Furthermore, NSCLC patients with wild-type EGFR are not eligible for EGFR-TKIs, and certain gene alternations such as KRAS mutations, in-frame insertion mutations in exon 20 of HER2, and loss of PTEN, can cause primary resistance [8]. Here, ERBB2 is linked to non-small cell lung carcinoma.